Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
In the last years the onset of new therapies changed the management of malignant melanoma. Anti CTLA-4 antibody ipilimumab was the first drug to achieve a significant improvement in survival of advanced stage melanoma. This new therapeutic agent is characterized by a number of side effects that are totally different from those of traditional chemotherapy, mainly caused by the immune system activation. The purpose of this paper is to underline the central role of ipilimumab in the treatment of metastatic melanoma and to characterize related adverse events in terms of incidence, duration and severity of presentation. The early recognition of these side effects is crucial in order to ensure an appropriate management of the toxicities, thus reducing the long term clinical sequelae and the inappropriate treatment discontinuation.
['Savoia|Paola|P|', 'Astrua|Chiara|C|', 'Fava|Paolo|P|']
D000911:Antibodies, Monoclonal D060908:CTLA-4 Antigen D002986:Clinical Trials as Topic D006801:Humans D007167:Immunotherapy D000074324:Ipilimumab D008545:Melanoma D012878:Skin Neoplasms
ipilimumab toxicity anti-CTL-A4 immunotherapy melanoma treatment